The oncological and reproductive outcomes of fertility-preserving treatments for stage 1 grade 1 endometrial carcinoma: a systematic review and meta-analysis

References

• Age of Women Giving Birth, 2021. Office for National Statistics. Available from: https://www.ons.gov.uk/aboutus/transparencyandgovernance/freedomofinformationfoi/ageofwomengivingbirth [Accessed 10 Feb 2021].
   Google Scholar
• Alonso, S., et al., 2015. Hysteroscopic surgery for conservative management in endometrial cancer: a review of the literature. Ecancermedicalscience, 9 (February), 505.
   PubMedGoogle Scholar
• Arciuolo, D., et al., 2022. TCGA molecular prognostic groups of endometrial carcinoma: current knowledge and future perspectives. International Journal of Molecular Sciences, 23 (19), 11684.
   PubMed Web of Science ®Google Scholar
• Barr, C.E., et al., 2021. Weight loss during intrauterine progestin treatment for obesity-associated atypical hyperplasia and early-stage cancer of the endometrium. Cancer Prevention Research, 14 (11), 1041–1050.
   PubMed Web of Science ®Google Scholar
• Cade, T.J., et al., 2013. Long-term outcomes after progestogen treatment for early endometrial cancer. The Australian & New Zealand Journal of Obstetrics & Gynaecology, 53 (6), 566–570.
   PubMed Web of Science ®Google Scholar
• Cancer Research UK, 2020. Uterine cancer incidence statistics. Cancer Research UK. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/uterine-cancer/incidence#heading-Two [Accessed 11 Mar 2020].
   Google Scholar
• Catena, U., et al., 2022. Fertility-sparing treatment for endometrial cancer and atypical endometrial hyperplasia in patients with lynch syndrome: molecular diagnosis after immunohistochemistry of MMR proteins. Frontiers of Medicine, 9 (August), 948509.
   Google Scholar
• Chae-Kim, J., et al., 2021. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. International Journal of Gynecological Cancer, 31 (12), 1499–1505.
   PubMedGoogle Scholar
• Choi, M.C., et al., 2013. Fertility preservation via photodynamic therapy in young patients with early-stage uterine endometrial cancer: a long-term follow-up study. International Journal of Gynecological Cancer, 23 (4), 698–704.
   PubMed Web of Science ®Google Scholar
• Chung, Y.S., et al., 2021. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer. American Journal of Obstetrics and Gynecology, 224 (4), 370.e1–370.e13.
   PubMed Web of Science ®Google Scholar
• Coll-de la Rubia, E., et al., 2020. Prognostic biomarkers in endometrial cancer: a systematic review and meta-analysis. Journal of Clinical Medicine, 9 (6), 1900.
   PubMed Web of Science ®Google Scholar
• Concin, N., et al., 2021. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer, 31 (1), 12–39.
   PubMed Web of Science ®Google Scholar
• De Marzi, P., et al., 2015. Hysteroscopic resection in fertility-sparing surgery for atypical hyperplasia and endometrial cancer: safety and efficacy. Journal of Minimally Invasive Gynecology, 22 (7), 1178–1182.
   PubMed Web of Science ®Google Scholar
• Deans, R. and Abbott, J., 2010. Review of intrauterine adhesions. Journal of Minimally Invasive Gynecology, 17 (5), 555–569.
   PubMed Web of Science ®Google Scholar
• Dominguez-Valentin, M., et al., 2020. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective lynch syndrome database. Genetics in Medicine, 22 (1), 15–25.
   PubMed Web of Science ®Google Scholar
• Dong, H., et al., 2021. Whether preoperative hysteroscopy increases the dissemination of endometrial cancer cells: a systematic review and meta-analysis. The Journal of Obstetrics and Gynaecology Research, 47 (9), 2969–2977.
   PubMed Web of Science ®Google Scholar
• Duska, L.R., et al., 2001. Endometrial cancer in women 40 years old or younger. Gynecologic Oncology, 83 (2), 388–393.
   PubMed Web of Science ®Google Scholar
• Falcone, F., et al., 2017. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. Journal of Gynecologic Oncology, 28 (1), e2.
   PubMed Web of Science ®Google Scholar
• Fan, Z., et al., 2018. Fertility-preserving treatment in young women with grade 1 presumed stage IA endometrial adenocarcinoma: a meta-analysis. International Journal of Gynecological Cancer, 28 (2), 385–393.
   PubMed Web of Science ®Google Scholar
• Fukui, Y., et al., 2017. Polycystic ovarian morphology may be a positive prognostic factor in patients with endometrial cancer who achieved complete remission after fertility-sparing therapy with progestin. Asian Pacific Journal of Cancer Prevention, 18 (11), 3111–3116.
   PubMedGoogle Scholar
• Gallos, I.D., et al., 2012. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology, 207 (4), 266.e1–266.e12.
   PubMed Web of Science ®Google Scholar
• Giampaolino, P., et al., 2019. Hysteroscopic endometrial focal resection followed by levonorgestrel intrauterine device insertion as a fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial cancer: a retrospective study. Journal of Minimally Invasive Gynecology, 26 (4), 648–656.
   PubMed Web of Science ®Google Scholar
• Giampaolino, P., et al., 2022. Fertility-sparing approach in patients with endometrioid endometrial cancer grade 2 stage IA (FIGO): a qualitative systematic review. BioMed Research International, 2022, 4070368-15.
   Web of Science ®Google Scholar
• Gotlieb, W.H., et al., 2003. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstetrics and Gynecology, 102 (4), 718–725.
   PubMed Web of Science ®Google Scholar
• Guillon, S., et al., 2019. A systematic review and meta-analysis of prognostic factors for remission in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma. International Journal of Gynaecology and Obstetrics, 146 (3), 277–288.
   PubMed Web of Science ®Google Scholar
• Hahn, H.-S., et al., 2009. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. International Journal of Gynecological Cancer, 19 (6), 1068–1073.
   PubMed Web of Science ®Google Scholar
• Han, A.R., et al., 2009. Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia. International Journal of Gynecological Cancer, 19 (1), 147–151. https://ijgc.bmj.com/content/19/1/147.abstract.
   PubMed Web of Science ®Google Scholar
• JASP Team, 2020. JASP (version 0.14.1). Available from: https://jasp-stats.org/.
   Google Scholar
• Kim, M.K., et al., 2013. Combined medroxyprogesterone acetate/levonorgestrel–intrauterine system treatment in young women with early-stage endometrial cancer. American Journal of Obstetrics and Gynecology, 209 (4), 358.e1–358.e4.
   PubMed Web of Science ®Google Scholar
• Koskas, M., et al., 2012. Progestin treatment of atypical hyperplasia and well-differentiated adenocarcinoma of the endometrium to preserve fertility. Anticancer Research, 32 (3), 1037–1043.
   PubMed Web of Science ®Google Scholar
• Kudesia, R., et al., 2014. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma. American Journal of Obstetrics and Gynecology, 210 (3), 255.e1–255.e4.
   PubMed Web of Science ®Google Scholar
• La Russa, M., et al., 2018. Conservative management of endometrial cancer: a survey amongst European clinicians. Archives of Gynecology and Obstetrics, 298 (2), 373–380.
   PubMed Web of Science ®Google Scholar
• Lajer, H., et al., 2012. Survival after stage IA endometrial cancer; can follow-up be altered? A Prospective Nationwide Danish Survey. Acta Obstetricia et Gynecologica Scandinavica, 91 (8), 976–982.
   PubMed Web of Science ®Google Scholar
• Lee, N.K., et al., 2007. Prognostic factors for uterine cancer in reproductive-aged women. Obstetrics and Gynecology, 109 (3), 655–662.
   PubMed Web of Science ®Google Scholar
• Lewin, S.N., 2011. Revised FIGO staging system for endometrial cancer. Clinical Obstetrics and Gynecology, 54 (2), 215–218.
   PubMed Web of Science ®Google Scholar
• Lucchini, S.M., et al., 2021. Updates on conservative management of endometrial cancer in patients younger than 45 years. Gynecologic Oncology, 161 (3), 802–809.
   PubMed Web of Science ®Google Scholar
• Mao, Y., et al., 2010. Outcomes of conservative therapy for young women with early endometrial adenocarcinoma. Fertility and Sterility, 93 (1), 283–285.
   PubMed Web of Science ®Google Scholar
• Mazzon, I., et al., 2010. Conservative surgical management of stage Ia endometrial carcinoma for fertility preservation. Fertility and Sterility, 93 (4), 1286–1289.
   PubMed Web of Science ®Google Scholar
• Microsoft Corporation, 2018. Microsoft Excel (version 2019 16.0). Available from: https://office.microsoft.com/excel.
   Google Scholar
• Minaguchi, T., et al., 2007. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Letters, 248 (1), 112–122.
   PubMed Web of Science ®Google Scholar
• Minig, L., et al., 2011. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Annals of Oncology, 22 (3), 643–649.
   PubMed Web of Science ®Google Scholar
• Morrison, J., et al., 2021. British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: recommendations for practice. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 270, 50–89.
   PubMed Web of Science ®Google Scholar
• Niwa, K., et al., 2005. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. British Journal of Gynecology, 112 (3), 317–320.
   Web of Science ®Google Scholar
• Obermair, A., et al., 2020. Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstetrics & Gynecology Science, 63 (4), 417–431.
   PubMedGoogle Scholar
• Ohyagi-Hara, C., et al., 2015. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature. Archives of Gynecology and Obstetrics, 291 (1), 151–157.
   PubMed Web of Science ®Google Scholar
• Park, H., et al., 2012. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium. Archives of Gynecology and Obstetrics, 285 (2), 473–478.
   PubMed Web of Science ®Google Scholar
• Park, J.-Y., et al., 2013a. Hormonal therapy for women with stage Ia endometrial cancer of all grades. Obstetrics and Gynecology, 122 (1), 7–14.
   PubMed Web of Science ®Google Scholar
• Park, J.-Y., et al., 2013b. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstetrics and Gynecology, 121 (1), 136–142.
   PubMed Web of Science ®Google Scholar
• Parlakgumus, H.A., et al., 2014. Fertility outcomes of patients with early stage endometrial carcinoma. The Journal of Obstetrics and Gynaecology Research, 40 (1), 102–108.
   PubMed Web of Science ®Google Scholar
• Pashov, A.I., Tskhay, V.B., and Ionouchene, S.V., 2012. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study. Gynecological Endocrinology, 28 (7), 559–561.
   PubMed Web of Science ®Google Scholar
• Perri, T., et al., 2011. Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved. International Journal of Gynecological Cancer, 21 (1), 72–78.
   PubMed Web of Science ®Google Scholar
• Raffone, A., et al., 2021. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: a multi-center study. Gynecologic Oncology, 161 (3), 795–801.
   PubMed Web of Science ®Google Scholar
• Raglan, O., et al., 2019. Risk factors for endometrial cancer: an umbrella review of the literature. International Journal of Cancer, 145 (7), 1719–1730.
   PubMed Web of Science ®Google Scholar
• Randall, T.C. and Kurman, R.J., 1997. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstetrics and Gynecology, 90 (3), 434–440.
   PubMed Web of Science ®Google Scholar
• Rodolakis, A., et al., 2023. ESGO/ESHRE/ESGE guidelines for the fertility-sparing treatment of patients with endometrial carcinoma. Facts, Views & Vision in ObGyn, 15 (1), 3–23.
   PubMed Web of Science ®Google Scholar
• Shan, B.-E., et al., 2013. A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women. Archives of Gynecology and Obstetrics, 288 (5), 1115–1123.
   PubMed Web of Science ®Google Scholar
• Shan, W., et al., 2021. Conservative management of grade 2 stage IA endometrial carcinoma and literature review. The Journal of Obstetrics and Gynaecology Research, 47 (3), 984–991.
   PubMed Web of Science ®Google Scholar
• Shea, B.J., et al., 2017. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ (Clinical Research ed.), 358 (September), j4008.
   PubMedGoogle Scholar
• Shobeiri, M.J., et al., 2013. Fertility sparing treatment in young patients with early endometrial adenocarcinoma. Pakistan Journal of Medical Sciences, 29 (2), 651–655.
   PubMed Web of Science ®Google Scholar
• Siegel, R.L., Miller, K.D., and Jemal, A., 2016. Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66 (1), 7–30.
   PubMed Web of Science ®Google Scholar
• Slim, K., et al., 2003. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ Journal of Surgery, 73 (9), 712–716.
   PubMed Web of Science ®Google Scholar
• Tamauchi, S., et al., 2018. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer. The Journal of Obstetrics and Gynaecology Research, 44 (1), 151–156.
   PubMed Web of Science ®Google Scholar
• Terzic, M., et al., 2020. Fertility preservation in endometrial cancer patients: options, challenges and perspectives. Ecancermedicalscience, 14 (May), 1030.
   PubMedGoogle Scholar
• Travaglino, A., et al., 2018. Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment: a systematic review and meta-analysis. Acta Obstetricia et Gynecologica Scandinavica, 97 (12), 1415–1426.
   PubMed Web of Science ®Google Scholar
• Ushijima, K., et al., 2007. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. Journal of Clinical Oncology, 25 (19), 2798–2803.
   PubMed Web of Science ®Google Scholar
• Wang, C.-J., et al., 2014. Fertility-preserving treatment in young women with endometrial adenocarcinoma: a long-term cohort study. International Journal of Gynecological Cancer, 24 (4), 718–728.
   PubMed Web of Science ®Google Scholar
• Wang, F., et al., 2017. Fertility preserved hysteroscopic approach for the treatment of stage Ia endometrioid carcinoma. International Journal of Gynecological Cancer, 27 (9), 1919–1925.
   PubMed Web of Science ®Google Scholar
• Wang, Q., et al., 2015. Fertility-conservation combined therapy with hysteroscopic resection and oral progesterone for local early stage endometrial carcinoma in young women. International Journal of Clinical and Experimental Medicine, 8 (8), 13804–13810.
   PubMed Web of Science ®Google Scholar
• Yahata, T., et al., 2006. Long-term conservative therapy for endometrial adenocarcinoma in young women. Human Reproduction, 21 (4), 1070–1075.
   PubMed Web of Science ®Google Scholar
• Yamazawa, K., et al., 2007. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Human Reproduction, 22 (7), 1953–1958.
   PubMed Web of Science ®Google Scholar
• Yang, B.-Y., et al., 2020. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. British Journal of Gynecology, 127 (7), 848–857.
   Web of Science ®Google Scholar
• Yang, H.-C., Liu, J.-C., and Liu, F.-S., 2019. Fertility-preserving treatment of stage IA, well-differentiated endometrial carcinoma in young women with hysteroscopic resection and high-dose progesterone therapy. Taiwanese Journal of Obstetrics & Gynecology, 58 (1), 90–93.
   PubMed Web of Science ®Google Scholar
• Yu, M., et al., 2009. Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium. Fertility and Sterility, 92 (6), 2122–2124.
   PubMed Web of Science ®Google Scholar